Propanc Biopharma
PPCB
Propanc Biopharma (PPCB) news
Recent news
Propanc Biopharma - PRP shows marked reduction in metastatic burden in PDAC models
AInvest Wire · 7d agoPropanc's PRP shows >90% tumor growth inhibition in PDAC
AInvest Wire · 7d agoPropanc to start phase 1B PRP trial in 1Q 2027
AInvest Wire · 7d agoPropanc Biopharma reports data showing 90% tumor growth inhibition with PRP in pancreatic cancer models, contrasting profile with Revolution Medicines' Daraxonrasib
AInvest Wire · 7d agoPropanc Biopharma - To initiate phase 1B PRP study in February 2027 for up to 50 patients
Propanc Biopharma, Inc. (Nasdaq: PPCB) announced plans to initiate a Phase 1b first-in-human (FIH) study of its lead product candidate, PRP, in February 2027 . The open-label, two-part study will enroll up to 50 patients with advanced solid tumors, including pancreatic, ovarian, and refractory…
AInvest Wire · Sep 16, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.